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In the 1890s, William Coley, an orthopaedic surgeon from New York developed a 
novel paradigm for the treatment of cancer. He started to treat his patients with bacterial 
cultures of Streptococcus pyogenes based on reports of cancer regression in a patient 
who had earlier suffered from an acute infection with S.pyogenes [1,2]. Over 10% of 
patients achieved tumour regression following injection with these “Coley’s Toxins”, as 
the treatment came to be called [3]. Thus, the field of immunotherapy was born but it 
took several decades for scientists to discover the immunological basis of tumour 
regression in patients treated with Coley’s toxins. The ability to evade immune attack is 
now recognized as a functional hallmark of cancer [4]. 
Dendritic cells (DC) are classical antigen-presenting cells (APC) that play a crucial 
role in the adaptive and innate immune response [5,6]. DC are observed in various 
human and murine tumours and are necessary for priming the immune response to 
cancer [7]. They are capable of capturing tumour-associated antigens (TAA) from dead 
or living cancer cells and presenting it on MHC-I and MHC-II to T cells in tumour-
draining lymph nodes [8,9]. In particular, the capacity of DC to cross-present acquired 
TAA to CD8+ T cells is required for the activation of CD8+ cytotoxic T lymphocytes (CTL) 
that are capable of directly killing neoplastic cells [10]. It is well-known that tumour cells 
can escape immune attack by various mechanisms of immunosuppression. Several TAA 
are of self-origin and are recognized as such by T cells preventing immune attack [8] 
[10]. Also, insufficiently matured tumour infiltrating DC can lead to the induction of T 
cell anergy or regulatory T cells (Treg). Moreover, the tumour microenvironment is 
immunosuppressive, expressing molecules and cytokines that shut down effector 
responses, such as PD-L1 [9,11]. Therefore, immune checkpoint blockade therapy, for 
example, targeting of the inhibitory cell-surface molecules programmed-death ligand 1 
(PD-L1) and programmed death-1 (PD-1), is now recognized as highly effective 
immunotherapy for various forms of cancer [12,13]. However, most patients treated with 
these drugs do not achieve durable anti-tumour immunity and clinical response [12]. 
Thus, research on the use of dendritic cell-based vaccines in cancer is of tremendous 
value in the quest to achieve long-lasting and protective cancer immunity [11]. DC-
based immunotherapy offers the potential to efficiently prime tumour specific CTL 
thereby working in tandem with immune checkpoint blockade or improve outcomes in 
patients where PD-1/PD-L1 therapy fails to achieve clinical response. It is also pertinent 
to mention that T cell co-stimulatory molecules may be targeted directly to mediate T 
cell activation and effector function [14]. In particular, members of the tumour necrosis 
factor receptor super family (TNFRSF), such as OX40 (CD134) and 4-1BB (CD137) have 
been widely investigated for their role in tumour immunotherapy and are currently 
undergoing clinical trials [15]. In a recent study using the B16 mouse melanoma model, 
a therapeutic CD8+ response was induced by co-stimulation using OX-40 and 4-1BB 
antibodies together with transferred tumor-unrelated CD4+ T helper cells [16]. In addition 
Madridge Journal of Vaccines
2Madridge J Vacc. Volume 1 Issue 1
to their respective ligands, OX40 and 4-1BB are reported to 
be expressed on dendritic cells [17] and targeting 4-1BB with 
4-1BBL transfected cells increased maturation and cytokine 
production (IL-6 and IL-12) in murine splenic DCs [18]. These 
findings suggest that in future studies it is important to 
investigate the effects of co-stimulatory therapies on DC 
activation to gain a comprehensive understanding of their 
mechanisms of action.
To date, DC-based immunotherapy has been translated 
to the clinic primarily for melanoma, prostate cancer, 
glioblastoma multiforme and renal cell cancer [6]. Most of 
these treatments involve the use of ex vivo manipulated DC. 
Of these, Sipuleucel-T, an autologous DC product primed with 
a fusion protein of prostatic acid phosphatase (PAP) and GM-
CSF, is one of the most clinically beneficial ex vivo vaccines to 
date [19,20]. However, this approach is associated with a high 
cost and labour-intensive production techniques [21]. For 
instance, a recent cost analysis in Belgium for acute myeloid 
leukaemia patients receiving a DC vaccine showed the cost of 
a GMP vaccine preparation to be € 20,450 per patient [22]. As 
such, several studies have focused on approaches that target 
DC in vivo [23]. These approaches may be easy to scale up due 
to their cost-effectiveness and harbour the potential to induce 
long-term immunity by activating natural DC subsets [21].
In 1993, Dranoff et al. demonstrated that DC could be 
activated in vivo against B16 melanoma in mice by injection of 
irradiated virally- transduced cells that expressed granulocyte-
macrophage colony-stimulating factor (GM-CSF) [24]. 
Subsequently, pre-clinical studies showed that GM-CSF is 
essential for DC recruitment, maturation and antigen-
presentation, while IL-12 produced by mature DC is capable 
of activating effector lymphocytes [25,26,27]. GVAX® (Cell 
Genesys, San Francisco, CA) vaccines consist of irradiated 
autologous or allogeneic, tumour cells that are virally-
transduced with adenoviruses or retroviruses to produce GM-
CSF [28]. They have now been tested in clinical trials against 
various types of cancers and have been shown to elicit anti-
tumour immune responses [29]. In an early phase I/II clinical 
study of patients with prostate cancer, allogeneic GM-CSF 
cells were tolerated safely and showed increased levels of 
antibodies to tumour-antigens and the infiltration of CD1a+ 
DC and CD68+ macrophages at injection sites [30]. However, a 
phase III trial using allogeneic GVAX® was observed not to be 
superior to current treatments. Nevertheless, studies continue 
to investigate the use of GM-CSF to prime anti-tumour 
responses in other cancer types [29,30,31]. A series of seminal 
papers have also demonstrated the complex tumour 
microenvironment that must be modulated to achieve long-
term anti-tumour immunity. Wada et al. showed in an 
autochthonous prostate cancer model, that cyclophosphamide 
could promote anti-tumour immunity by transiently depleting 
Treg in the tumour draining lymph nodes but not those in 
peripheral circulation [32]. Studies in human cases of 
pancreatic ductal adenocarcinoma (PDAC) using an allogeneic 
GVAX® in combination with low-dose cyclophosphamide to 
deplete regulatory T cells (Treg), induced intra-tumoural 
tertiary lymphoid aggregates. Post-GVAX T-cell infiltration 
and aggregate formation resulted in the up regulation of 
immune-regulatory mechanisms (e.g. PD-1–PD-L1), suggesting 
that they may be better responders to immune checkpoint 
and other immune modulatory therapies than vaccine naïve 
tumours [33]. These observations suggest a crucial role for 
GM-CSF due to its direct stimulatory effects on DC. The 
aforementioned studies also provide insight into the design 
of combinatorial immunotherapies to overcome the various 
suppressor mechanisms at play in the tumour micro-environment: 
Given these considerations, a recent phase I trial was conducted 
using tumour-associated peptides (TUMAP) from renal cell 
cancer in combination with GM-CSF and preceded by a single-
dose of cyclophosphamide [34]. Treatment with the IMA901 
vaccine, comprising 9 HLA class-I restricted TUMAP, in 
combination with GM-CSF and cyclophosphamide resulted in 
prolonged survival [35]. This was the first study to report a 
discernable clinical efficacy associated with an anti-tumour 
peptide vaccine. The clinical response was also shown to be 
associated with reduced numbers of Treg. A phase III trial is 
currently underway to further study the therapeutic efficacy 
of the IMA901 vaccine in patients [34]. The success of this 
treatment shows the need for eliciting a multifaceted immune 
response to achieve clinical responses. The anti-tumour 
immunity induced by GM-CSF is favourable in some forms of 
cancer and unfavourable in others by inducing a suppressive 
phenotype [36]. Thus, there is a continued need for agents 
that can target DC selectively and with high specificity.
Hawiger et al. first demonstrated in 2001 that antigen 
could be directly targeted to DC in vivo [37]. The authors 
developed a fusion protein of hen-egg lysozyme (HEL) and a 
monoclonal antibody targeted to DEC-205, an endocytic 
receptor of the C-type lectin receptor (CLR) family. It was 
found that antigen could be delivered to DC which were then 
processed and presented efficiently to 3A9 transgenic T cells 
[37]. However, these T cells could not produce Th1 cytokines 
and after 7 days, became unresponsive to systemic challenge 
with the antigen. In comparison, concurrent treatment with 
anti-CD40 antibodies resulted in long-term T cell activation 
demonstrating the importance of secondary signals for DC 
maturation [37]. In mice, targeting HIV gag p24 to other CLRs 
such as Langerin, and Clec9A induced a CD8+ and Th1 immune 
response if co-treated with anti-CD40 [38]. Targeting to other 
receptors such as XCR1, which are expressed on cross-
presenting CD141+DC in humans and CD8+DC in mice, is an 
additional approach to induce not only CD8+ but also Th1 
responses [39]. Given the number of potential targets and 
adjuvants capable of modulating DC function in vivo, the use 
of nanoparticles warrants further consideration. Nanoparticles 
are nano-sized drug delivery systems that can be manipulated 
in a number of ways to boost cancer immunotherapy 
[40,41,42]. First, nanoparticle size and surface composition 
can be selectively designed to increase delivery to specific 
tissues and control systemic distribution. Second, the desired 
therapeutic can be encapsulated, embedded or conjugated to 
the surface. Thus, they can potentially serve as artificial APC 
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that contain both antigens and co-stimulatory molecules on 
their surface [41]. Third, nanoparticles can be designed with 
immunostimulatory biomaterials thus serving as both drug 
carriers and adjuvants [40,41]. Finally, nanoparticles are 
capable of sustained release of encapsulated substances 
providing a long-term therapeutic option and obviating the 
need for continuous treatment. Encapsulating cytotoxic anti-
cancer drugs can further boost immunotherapy by releasing 
tumour-associated antigens for uptake and cross-presentation 
by DC. Hence, nanoparticles are multi-functional platforms 
that are in theory more cost effective, scalable and versatile 
than ex vivo manipulated DC products. DC-targeted 
nanoparticle systems have not been widely studied but 
reports from the literature have shown their efficacy and 
applicability for immunotherapy. In January 2017, Shi et al. 
demonstrated that chitosan nanoparticles loaded with tumour 
cell lysates and targeted to DC by coating the surface with 
mannose resulted in DC activation and induction of anti-
tumour CTL responses [43]. Last year, a study reported the 
efficacy of RNA-nanoparticles in a phase I clinical trial in 3 
patients [44]. The authors described the generation of RNA-
lipid lipoplexes (RNA-LPX), that protected RNA in vivo and 
targeted it efficiently to various lymphoid DC and macrophage 
subsets. RNA-LPX encoding for the tumour antigens NY-
ESO-1, MAGE-A3, tyrosinase and TPTE were used in 3 patients 
with advanced melanoma. IFNα and antigen-specific T cell 
responses were observed in all patients [44]. One patient had 
undergone resection of metastatic lesions and thus was 
tumour-free at the time of the submission of the manuscript, 
while the two other patients demonstrated regression and 
stable disease respectively [44]. This vaccine could be given 
systemically and was not associated with any major adverse 
effects. This was the first study of its kind using a RNA-
nanoparticle system which may have broad applications for 
tumour immunotherapy. First, RNA can be used to encode 
several tumour antigens and neoantigens. Second, studies in 
mice with RNA-LPX showed a wide systemic distribution of 
the nanoparticle to lymphoid DC, potentially increasing the 
number of responding cells and thus the potency of the 
treatment [44]. 
The global burden of cancer continues to rise and 
immunotherapy heralds the promise of long-term control 
and eventual cure of the disease. Using DC vaccines to 
mediate anti-tumour immunity is now deemed a crucial factor 
for the success of combinatorial immunotherapy [7]. However, 
the prohibitive costs of GMP-grade manufacturing of human 
cell products preclude their use in many types of cancers and 
in many countries of the world. Alternatively, nanoparticles 
are biocompatible, low-risk and low-cost delivery platforms 
for immunotherapy. Moving forward, it will be essential to 
design multifunctional nanoparticles or “nanoparticle 
cocktails” that are capable of key immunotherapeutic 
functions. These include effectively targeting DC (e.g. DEC-
205), inducing maturation (e.g. anti-CD40), delivering TAA 
(e.g. RNA or tumour lysates), checkpoint blockade (e.g. anti-
PDL1) and finally, inducing tumour cytotoxicity (e.g. 
doxorubicin). Finally, an additional advantage of nanoparticles 
is their ability to be loaded with imaging agents [45,46]. This 
can allow oncologists to measure the infiltration of these 
nanoparticles in lymphoid tissue and analyze their interactions 
with immune cells to accurately determine the efficacy of the 
treatment. Therefore, further research in the context of 
immunotherapy stands to benefit significantly with these 
platforms and their inclusion in clinical trials promises to 
deliver low-cost multiparameter treatments that are essential 
for precision medicine.
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